New hope for Tough-to-Treat lymphoma
NCT ID NCT06630091
Summary
This study is testing whether a new drug called golidocitinib, given alone or with standard chemotherapy, can help control a rare and aggressive type of blood cancer called peripheral T-cell lymphoma (PTCL). The trial will enroll 30 adults newly diagnosed with PTCL to see if the treatment is safe and effective at keeping the cancer from progressing for at least two years. Researchers will also look for biological markers that might predict which patients respond best to the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.